These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86. Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. Naik RP; Streiff MB; Haywood C; Segal JB; Lanzkron S J Thromb Haemost; 2014 Dec; 12(12):2010-6. PubMed ID: 25280124 [TBL] [Abstract][Full Text] [Related]
87. Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia. Ghasemi A; Keikhaei B; Ghodsi R Iran J Ped Hematol Oncol; 2014; 4(3):114-7. PubMed ID: 25254090 [TBL] [Abstract][Full Text] [Related]
88. Meeting the emerging public health needs of persons with blood disorders. Parker CS; Tsai J; Siddiqi AE; Atrash HK; Richardson LC Am J Prev Med; 2014 Nov; 47(5):658-63. PubMed ID: 25245797 [TBL] [Abstract][Full Text] [Related]
89. Sickle cell disease: a neglected chronic disease of increasing global health importance. Chakravorty S; Williams TN Arch Dis Child; 2015 Jan; 100(1):48-53. PubMed ID: 25239949 [TBL] [Abstract][Full Text] [Related]
90. Testicular Tissue Banking for Fertility Preservation in Young Boys: Which Patients Should Be Included? Delgouffe E; Braye A; Goossens E Front Endocrinol (Lausanne); 2022; 13():854186. PubMed ID: 35360062 [TBL] [Abstract][Full Text] [Related]
91. Association of bone mineral density with peripheral blood cell counts and hemoglobin in Chinese postmenopausal women: A retrospective study. Li L; Ge JR; Chen J; Ye YJ; Xu PC; Li JY Medicine (Baltimore); 2020 Jul; 99(28):e20906. PubMed ID: 32664083 [TBL] [Abstract][Full Text] [Related]
92. Homozygous Deletion Alpha-Thalassemia and Hereditary Persistence of Fetal Hemoglobin, Two Genetic Factors Predictive the Reduction of Morbidity and Mortality During Pregnancy in Sickle Cell Patients. A Report from the Democratic Republic of Congo. Mikobi TM; Lukusa PT; Muamba JM; Rhama T Mediterr J Hematol Infect Dis; 2019; 11(1):e2019039. PubMed ID: 31308915 [TBL] [Abstract][Full Text] [Related]
93. Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy. Senol SP; Tiftik EN; Unal S; Akdeniz A; Tasdelen B; Tunctan B J Basic Clin Pharm; 2016 Mar; 7(2):49-59. PubMed ID: 27057126 [TBL] [Abstract][Full Text] [Related]
94. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547 [TBL] [Abstract][Full Text] [Related]
96. Iron metabolism and iron chelation in sickle cell disease. Walter PB; Harmatz P; Vichinsky E Acta Haematol; 2009; 122(2-3):174-83. PubMed ID: 19907155 [TBL] [Abstract][Full Text] [Related]
97. Thalassemia major and sickle cell disease in adolescents and young adults. Yacobovich J; Tamary H Acta Haematol; 2014; 132(3-4):340-7. PubMed ID: 25228560 [TBL] [Abstract][Full Text] [Related]
98. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients. Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137 [TBL] [Abstract][Full Text] [Related]